April 2017

Insights

Interview

Prostate Cancer Treatment Varies Between General Population, Diagnosed Men

01/11/2019

JCP Editors

Prostate cancer is the second most common cancer among men in the United States, as well as the third leading cause of cancer-related death.1 More than 160,000 men are diagnosed with prostate cancer annually, and...

...

01/11/2019

Journal of Clinical Pathways

Interview

Christiana Care Health System Pioneers Clinical Pathways in the Tri-State Area

01/11/2019

Clinical pathways are not new, but their prominence has grown in recent years. An increased focus on value-based medical care1 has brought strategies that provide optimal treatment at a favorable cost to the...

...

01/11/2019

Journal of Clinical Pathways

Feature

From the Field

Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplant Program

04/11/2017

Belinda R. Avalos , MD;

Abstract: The Levine Cancer Institute (LCI) of the Carolinas HealthCare System was established in Charlotte, NC, in 2010 as a primary through quaternary referral center. The Department of Hematologic Oncology and...

...

04/11/2017

Journal of Clinical Pathways

Research Reports

Length of Stay and Costs of COPD: Analysis of Hospitalized Patients Treated With Arformoterol or Nebulized Short-Acting Beta2-Agonists

04/11/2017

Tina Hunter , PhD;

Scott B. Robinson , PhD, MD;

Vamsi K. Bollu , PhD, MBA;

Krithika Rajagopalan , PhD;

Bernadette H. Johnson , MBA;

Frank R. Ernst , PharmD, MS;

Abstract: Hospitalization costs are substantial in chronic obstructive pulmonary disease (COPD). Little is known regarding the effect of long-acting beta2-agonists (LABAs) vs short-acting beta2-agonists (SABAs) on...

...

04/11/2017

Journal of Clinical Pathways

Column

Clinical Pathways GPS

Preparing for Take-Off: Readying Older Adults for Flight

04/11/2017

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Sevy Gambs , MBA, ALA, MSN-GR;

Older adults are at risk for a host of potential medical issues while traveling, arising from cognitive impairments such as Alzheimer disease, dementia or psychiatric disorders, and chronic conditions such as...

Older...

04/11/2017

Journal of Clinical Pathways

Pharma Insights

The Clash: Treatment Advances and Value Measurements in Oncology

04/11/2017

Jason Shafrin , PhD;

Larry Blandford , PharmD;

Cancer has or will affect nearly every person at some point in their lives, either directly or indirectly. The fight against cancer is central to society; in recent years, treatment advances and prevention strategies...

Cancer...

04/11/2017

Journal of Clinical Pathways

News

Conference Coverage

Academy of Managed Care Pharmacy Annual Meeting

04/11/2017

JCP Editors

The Academy of Managed Care Pharmacy (AMCP) is the leading professional organization for practitioners invested in the development and implementation of value-based care pathways within the managed care setting....

The...

04/11/2017

Journal of Clinical Pathways

Conference Coverage

ASCO Quality Care Symposium

04/11/2017

JCP Editors

Value-based medical care continues to gain traction in the oncology sphere, and tools for the developing, measuring, and implementing value measures in clinical practice are needed. The rapid introduction of new...

...

04/11/2017

Journal of Clinical Pathways

Department

Research in Review

Neurofeedback Reduces Nerve Damage From Chemotherapy in Cancer Survivors

04/11/2017

JCP Editors

Chemotherapy-induced peripheral neuropathy (CIPN) may be significantly reduced by electroencephalogram (EEG) neurofeedback training, according to research published in Cancer (published online March 3, 2017;...

...

04/11/2017

Journal of Clinical Pathways

Research in Review

Leukemia Survival Outcomes Differ Between Sites of Care

04/11/2017

JCP Editors

Sites of care may help explain survival differences between children and adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), according to research published...

Sites...

04/11/2017

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

April 2017

Insights

Feature

Column

News

Department

Current Issue

Special Reports

Subscribe

Volume 3

Specialties

Events

Year Round Education

HMP Global Products